Enabling independent CytoSorb® Therapy
*Not authorized / cleared / approved for human use in the USA
CE-marked under MDR since 06/2024
Provide independent platform for hemoadsorption when CytoSorbents therapies are required.
PuriFi is designed for the standalone application of CytoSorb®, enabling straightforward setup and familiar handling for extracorporeal circuit trained personnel. With its compact and mobile design, PuriFi can be used in the Emergency Room, Intensive Care Unit, or Intermediate Care settings.
PuriFi Features
Intuitive touchscreen interface
Maintenance-free pressure monitoring
Pre-assembled adult and pediatric line kit
Auto-leveling bubble catcher
Temperature management option
Setup in approx. 10 minutes including automated adsorber priming
Engineered for independent application of CytoSorb® as stand-alone system
Extensive clinical experience with CytoSorb
With more than 300,000 hemoadsorption treatments performed worldwide over the past ten years, CytoSorb® technology has been extensively used in clinical practice and continuously monitored for safety and performance.
Over 1,100 scientific contributions
CytoSorbents’ hemoadsorption technology is supported by a large and growing body of peer-reviewed literature and clinical evidence. Over 1,100 scientific contributions, including over 700 peer-reviewed publications.
Clinical experience across multiple indications
Research and clinical use of CytoSorbents’ hemoadsorption therapies have been reported in cardiovascular, renal, hepatic, and critical-care settings.
PuriFi at a glance
- Mitzner et al. J Clin Med. 2023;12(23):7199
- Schmoeckel et al., J Throm & Thrombolysis 2024; epub
- Doukas et al., J Clin Med 2023; 12:546
- Haidari et al., ICV&TS 2023; 36(1):ivad010
- Nemeth et al., ESC Heart Failure 2024; 11(2):772-782
- Grafe et al., Ren Fail 2023; 45(2):2259231
- Haselwanter et al., Sci Rep 2024; 14(1):11309
- Jansen et al., Critical Care 2023; 27(1):117
- Akil et al., J Clin Med 2022; 11(20):5990
PuriFi IFU Intended Use (07/2025):
PuriFi is indicated when a hemoperfusion procedure is prescribed by a physician and provides the required system environment of the prescribed adsorption column. The system environment includes equipment (PuriFi) used to drive, control, and monitor extracorporeal blood circulation, the tube set, and associated accessories such as vascular access devices and their interconnections. When used together with CytoSorbents’ wholeblood adsorption columns (Device), the system is intended to remove specific molecules as specified in the adsorption columns’ Instructions for Use.